Elevated core-fucosylated IgG is a new marker for hepatitis B virus-related hepatocellular carcinoma

• Verfasst von: Yi, Chang-Hong [VerfasserIn]
• Verfasst von: Weng, Honglei [VerfasserIn]
• Verfasst von: Liebe, Roman [VerfasserIn]
• Verfasst von: Dooley, Steven [VerfasserIn]
• Titel: Elevated core-fucosylated IgG is a new marker for hepatitis B virus-related hepatocellular carcinoma
• Verf.angabe: Chang-Hong Yi, Hong-Lei Weng, Fei-Guo Zhou, Meng Fang, Jun Ji, Cheng Cheng, Hao Wang, Roman Liebe, Steven Dooley, Chun-Fang Gao
• E-Jahr: 2015
• Jahr: 07 Jul 2015
• Umfang: 12 S.
• Fussnoten: Gesehen am 31.08.2017
• Titel Quelle: Enthalten in: OncoImmunology
• Ort Quelle: Abingdon : Taylor & Franics, 2012
• Jahr Quelle: 2015
• Band/Heft Quelle: 4(2015,12) Artikel-Nummer e1011503, 12 Seiten
• ISSN Quelle: 2162-402X
• DOI: doi:10.1080/2162402X.2015.1011503
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: diagnosis
• Sach-SW: hepatocellular carcinoma (HCC)
• Sach-SW: IgG
• Sach-SW: Lens culinaris agglutinin (LCA)
• Sach-SW: non-invasive biomarker
• Sach-SW: tissue array
• K10plus-PPN: 1562940716

Abstract

Immunoglubulin G (IgG) and its abnormal glycosylations are associated with carcinogenesis. The present study investigates the relationship between cancer-derived IgG and clinicopathological characteristics in hepatocellular carcinoma (HCC) and assesses the value of serum N-glycosylated IgG in diagnosing and monitoring hepatitis B virus (HBV)-related HCC. Tissue microarray analysis of 90 HCC tissues showed that HCC patients with IgG immunopositivity had higher levels of core-fucosylated α fetoprotein (AFP-L3), larger tumors, and a higher incidence of portal vein tumor thrombus. HCC-derived IgG stimulated the growth of liver cancer cells in vitro. HCC patients presented a significantly increased fraction of Lens culinaris agglutinin binding IgG (core-fucosylated IgG, IgG-L3) among total serum IgG. The clinical diagnostic performance of serum IgG-L3% was evaluated in 3 case-control studies (1 training set and 2 validation cohorts), including 293 patients with HCC, 131 with liver cirrhosis, 132 HBV carriers, and 151 healthy controls. IgG-L3% had better general diagnostic performance than AFP in the training set and validation cohort 1 (accuracy: 81.33-85.11% versus 63.33-78.61%). In validation cohort 2, where we aimed to assess the efficiency of IgG-L3% in patients with AFP-negative HCC, the diagnostic accuracy of IgG-L3% was 72.54-73.60%. Finally, a longitudinal evaluation based on 31 HCC patients demonstrated that IgG-L3% decreased in 24 patients after curative surgery. The remaining 7 patients showed elevated IgG-L3% and post-operative recurrence. HCC patients with higher IgG-L3% had poor survival during a 3-year follow up. We conclude that HCC-derived IgG is correlated with progressive behavior of HCC. Therefore, elevated core-fucosylated IgG is a new diagnostic and prognostic marker in HBV-related HCC.